2019-4-4，美国ICER认为Biogen和Novartis应该降低其SMA药物Spinraza和Zolgensma价格。Spinraza第一年的治疗价格为75万美元，之后为37.5万美元。一次性治疗Zolgensma的价格可能为400万美元。
As treatments for rare diseases and gene therapies make strides on the US market, the issue of pricing is once again center stage. Biogen should cut the price of its spinal muscular atrophy (SMA) treatment Spinraza and the price for Novartis’ one-shot Zolgensma — which is expected to win FDA approval by May — is justifiable up to $1.5 million, Boston-based ICER concluded on Wednesday.
